TD Cowen analyst Tyler Van Buren has reiterated their bullish stance on IMNM stock, giving a Buy rating yesterday.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Tyler Van Buren’s rating is based on the promising potential of Immunome’s varegacestat, a gamma secretase inhibitor currently in Phase III development for desmoid tumors. The drug has shown strong efficacy in Phase II trials, with a high overall response rate and significant reductions in tumor size and volume.
The anticipated Phase III data, expected by year-end, could further solidify varegacestat’s best-in-class status, potentially leading to substantial value creation for Immunome. Additionally, the strategic acquisition of this asset at a relatively low upfront cost positions the company well for future growth, contributing to the Buy rating.
In another report released yesterday, LifeSci Capital also initiated coverage with a Buy rating on the stock with a $20.00 price target.